Universitätsklinikum Würzburg

Hospital


Location: Würzburg, Germany (DE) DE

ISNI: 0000000113787891

ROR: https://ror.org/03pvr2g57

Show on Map:


close-button

Types of publications

Journal article
Book chapter / Article in edited volumes
Authored book
Translation
Thesis
Edited Volume
Conference contribution
Other publication type
Unpublished / Preprint

Publication year

From
To

Abstract

Journal

Laryngeal Mucosal Tumor Mapping with Narrow Band Imaging and Confocal Laser Endomicroscopy () Atkins A, Koch C, James S, Wodeyar A, Sievert M, Goncalves M, Jeyarajan H, et al. Journal article Castleman’s disease in the rheumatological practice () Schmalzing M, Sander O, Seidl M, Marks R, Blank N, Kötter I, Tiemann M, et al. Journal article Addressing inter individual variability in CSF levels of brain derived proteins across neurodegenerative diseases (2025) Mravinacová S, Bergström S, Olofsson J, de San José NG, Anderl-Straub S, Diehl-Schmid J, Fassbender K, et al. Journal article Imaging strategies for patients with multiple and/or severe injuries in the resuscitation room: a systematic review and clinical practice guideline update (2025) Huber-Wagner S, Braunschweig R, Kildal D, Bieler D, Prediger B, Hertwig M, Kugler C, et al. Journal article Distinct pathways for genetic and epigenetic predisposition in familial and bilateral Wilms tumor (2025) Wegert J, Appenzeller S, Treger TD, Streitenberger H, Ziegler B, Bausenwein S, Vokuhl C, et al. Journal article Complete revascularization versus culprit-lesion only PCI in patients with NSTEMI and multivessel disease – Design and rationale of the randomized COMPLETE-NSTEMI trial (2025) Feistritzer HJ, Jobs A, Zeymer U, Schneider S, Lauten P, Ferenc M, Weferling M, et al. Journal article Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial (2025) Gani C, Fokas E, Polat B, Ott O, Diefenhardt M, Königsrainer A, Böke S, et al. Journal article Conditional progression-free survival in patients with metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with first-line ribociclib and endocrine therapy: real-world data from the RIBANNA study (2025) Decker T, Brucker C, Engel A, Fasching P, Göhler T, Jackisch C, Janssen J, et al. Journal article Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma (2025) Dummer R, Sandhu S, Miller WH, Butler MO, Taylor MH, Heinzerling L, Blank CU, et al. Journal article Update Breast Cancer 2024 Part 3 – Patients with Advanced Stage Breast Cancer (2025) Lüftner D, Kolberg HC, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, et al. Journal article, Review article